L803-mts
Myr-N-GKEAPPAPPQSpP-NH2 Lyophilized white solid. Supplied as a trifluoroacetate salt. HYGROSCOPIC. PACKAGED UNDER INERT GAS. A cell-permeable myristoylated form of GSK-3b Peptide Inhibitor (Cat. No. 361545) with a glycine spacer. Acts as a selective, substrate-specific, competitive inhibitor of GSK-3b (IC50 = 40 µM). Does not affect the activities of Cdc2, PKB, and PKC. Shown to mimic insulin action, and activate glycogen synthase activity (~2.5-fold) in HEK293 cells and improve glucose tolerance in diabetic mice. Displays in vivo stability. Purity: ≥98% by HPLC. Myr-N-Gly-Lys-Glu-Ala-Pro-Pro-Ala-Pro-Pro-Gln-Ser(PO3H)-Pro-NH2 Ref.: Plotkin, B., et al. 2003. J. Pharmacol. Exp. Ther. 305, 974.
This product is covered by one or more US patents and/or patent applications and foreign counter-parts owned by Tel Aviv University Future Technology LP, a limited partnership formed under the laws of Israel. Purchase of this product conveys a non-exclusive license to use the product for research purposes only. Purchase of this product does not convey the right to (i) incorporate or use the product in the manufacture of any commercial product, (ii) sell or otherwise transfer the product to any third party, or (iii) use the product to provide any commercial service. THE PRODUCT IS NOT FOR USE IN HUMANS. For information on purchasing a license to this product for purposes other than research, contact VP Business Development, Ramot at Tel Aviv University Ltd., Tel Aviv University, Licensor-Aviv, Tel Aviv 61392, Israel, Phone: +972 3 640 6608; Fax: +972 3 640 6675. |
